IP Library Granted Patent US 11,130,970
Granted Patent B2
US 11,130,970 · App. 17/179,193 · Granted Sep 28, 2021

Nucleic acid-guided nucleases

Inventors: Andrew Garst (Boulder, CO); Ryan T. Gill (Boulder, CO); Tanya Elizabeth Warnecke Lipscomb (Boulder, CO)
Assignee: Inscripta, Inc.
C12N15/902C12N9/22C12N15/11C12N15/111C12N15/70C12N15/81C12N15/85C12N15/905C12N15/907C12N2310/20C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,130,970
App. No.
17/179,193
Granted
Sep 28, 2021
Kind
B2
Abstract

Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.

Claims (24)

1. A nucleic acid-guided nuclease system comprising:

(a) a nucleic acid having at least 95% identity to the nucleotide sequence of SEQ ID No: 24 or SEQ ID No: 44, wherein the nucleic acid encodes a nucleic acid-guided nuclease comprising the amino acid sequence of SEQ ID No. 4;

(b) an engineered guide nucleic acid sequence capable of complexing with the nucleic acid-guided nuclease, wherein the engineered guide nucleic acid comprises any one of SEQ ID No. 84, SEQ ID No. 85, SEQ ID No. 87, SEQ ID No. 93, SEQ ID No. 94, SEQ ID No. 95 and SEQ ID No. 96;

(c) an editing sequence having a change in sequence relative to the sequence of a target region in a genome of a cell and a mutation in a protospacer adjacent motif (PAM);

wherein the system results in a genome edit in the target region in the genome of the cell facilitated by the nuclease, the engineered guide nucleic acid, and the editing sequence.

2. The system of claim 1 , wherein the engineered guide nucleic acid and the editing sequence are provided as a single nucleic acid.

3. The system of claim 1 , wherein the nucleic acid encoding the nucleic acid-guided nuclease is codon optimized for Escherichia coli.

4. The system of claim 1 , wherein the nucleic acid encoding the nucleic acid-guided nuclease is codon optimized for Saccharomyces cerevisiae.

5. The system of claim 1 , wherein the nucleic acid encoding the nucleic acid-guided nuclease is codon optimized for mammalian cells.

6. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 85.

7. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No: 84.

8. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 87.

9. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 93.

10. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 94.

11. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 95.

12. The system of claim 1 , wherein the engineered guide nucleic acid capable of complexing with the nucleic acid-guided nuclease comprises the nucleotide sequence of SEQ ID No. 96.

13. The system of claim 1 , wherein the target region is within a eukaryotic cell.

14. The system of claim 1 , wherein the target region is within a plant cell.

15. The system of claim 1 , wherein the target region is within a bacterial cell.

16. The system of claim 1 , wherein the target region is within a mammalian cell.

17. The system of claim 1 , wherein the target region is within a coding region of a protein.

18. The system of claim 1 , wherein the target region is within a non-coding region of a protein.

19. The system of claim 18 , wherein the target region is within a regulatory region of a protein.

20. A nucleic acid nuclease having at least 95% identity to the nucleotide sequence of SEQ ID No: 44.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Sep 15, 2025
From: INSCRIPTA, INC.,; MANUS INSCRIPTA, INC.
To: MANUS INSCRIPTA, INC.
Reel/Frame 072252/0203 →
SECURITY INTEREST Recorded Sep 8, 2025
From: MANUS BIO INC.; STO.PERU I LLC; STO.PERU II LLC; MANUS INTERMEDIATE INC.; MANUS INSCRIPTA, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 072836/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2021
From: GARST, ANDREW; GILL, RYAN T.; WARNECKE LIPSCOMB, TANYA ELIZABETH
To: MUSE BIOTECHNOLOGY, INC.
Reel/Frame 055337/0260 →
CHANGE OF NAME Recorded Feb 18, 2021
From: MUSE BIOTECHNOLOGY, INC.
To: INSCRIPTA, INC.
Reel/Frame 055338/0431 →
Continuity (5)
Continuation 16819896 · Mar 16, 2020
Continuation 16548631 · Aug 22, 2019
Continuation 15896433 · Feb 14, 2018
Continuation 15631989 · Jun 23, 2017
Related Publication 20210180090A1 · Jun 17, 2021
Cited By (1)
US 12,195,749